MyFinsight
Home
Blog
About
Contact
Back
Income Statement
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
source: myfinsight.com
Download
Download image
Net loss
attributable to common...
-$1,941,558
Non-controlling interest
-$63,932
Net loss
-$1,987,608
(-180.12%↓ Y/Y)
Interest income
$3,370
(664.17%↑ Y/Y)
Series b convertible
preferred stock 8...
-$17,882
Loss from operations
-$1,987,407
(-181.13%↓ Y/Y)
Interest expense
$3,096
(-1.24%↓ Y/Y)
Foreign currency gain
(loss)
-$475
Total costs and
expenses
$1,987,407
(181.13%↑ Y/Y)
General and
administrative costs
$1,654,031
(168.74%↑ Y/Y)
Research and development
costs
$333,376
(264.52%↑ Y/Y)
Back